Methods for the treatment of cellular proliferative disorders

Details Methods for the treatment of cellular proliferative disorders Methods for the treatment of cellular proliferative disorders

2006-05-30

2006-05-30

Huff, Sheela (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S005000, C435S007230, C436S063000, C436S064000

Reexamination Certificate

active

07052832

ABSTRACT:
The present invention relates to methods of identifying the susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling. The invention also pertains to methods using reovirus for the treatment of cellular proliferative disorders, and particularly cellular proliferative disorders wherein the proliferating cells exhibit constitutive MAPK phosphorylation, in mammals. In particular, the methods provide for reovirus treatment of mammals to treat proliferative disorders which include breast tumors, a subset of tumors in which mutation of the ras gene is not believed to play a significant role.

REFERENCES:
patent: WO 99/08692 (1999-02-01), None
patent: WO 00/50051 (2000-08-01), None
Norman et al. J of Clini Invest, Reovirus as a novel oncolytic agent, vol. 105, p. 1035-1038, 2000.
Coffey et al. Science, Reovirus therapy of tumors with activated ras pathway, vol. 282, p. 1332-1334, 1998.
Robinson et al. Curr. Opin. Cell Biol., Mitogen-activated protein kinase pathways, vol., 9, p. 180-186, 1997.
Current Protocols in Molecular Biology, Detection of MAP kinase signaling, unit 14.3, print publication date: Oct. 1998.
Wilsbacher et al. J Biol Chem., phosphorylatio of MAP kinases by MAP/ERK involves multiple regions of MAP kinase, vol. 272, p. 16988-16994, 1999.
von Lintig et al, Breast Cancer Research and Treatment,Ras activatioin human breast c vol. 62, p. 51-62, 2000).
Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. Jun. 15, 1998; 17(12):3351-3362..
Nguyen DH, Catling AD, Webb DJ, Sankevic M, Walker La, Somlyo AV, Weber MJ, Gonias SL. J Cell Biol. Jul. 12, 1999; 146(1): 146-164. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulat.
Archer et al. (1995),Br. J. Cancer72:1259-1266.
Armstrong, G.D. et al. (1984),Virology138:37-48.
Barbacid, M.,Annu. Rev. Biochem., 56:779-827 (1987).
Baselga et al. (1996),J. Clin. Onc. 14:737-744.
Bos, J. (1989)Cancer Res. 49:4682-4689.
Carter et al. (1992),PNAS89:4285-4289.
Chandron and Nibert, “Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle”,J. of Virology72(1):467-475 (1998).
Chaubert, P. et al. (1994),Am. J. Path. 144:767-775.
Clark et al. (1995),Science268:233-239.
Clark et al. (1996),Intl. J. Cancer65:186-191.
Cuff et al., “Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract”,Toxicological Sciences42(2):99-108 (1998).
DiDomenico et al. (1996),Cancer Res. 56:4516-4521.
Duncan et al., “Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein”,Virology182(2):810-819 (1991).
Dvorak et al. (1988),Am J Path133:95-109.
Gentsch, J.R.K. and Pacitti, A.F. (1985),J. Virol. 56:356-364.
Harwerth et al. (1992),J Biol Chem267:15160-15167.
Hudziak et al. (1989),Mol Cell Biol9:1165-1172.
Hung et al. (1995),Gene159:65-71.
Jacobs et al. (1983),Cancer Res43:1696-1702.
Janes, P. W., et al. (1994)Oncogene9:3601-3608.
Jardines et al. (1993)Pathobiology61:268-282.
Koenders et al. (1991),Cancer Res51:4544-4548.
Lee. J.M. et al. (1993)PNAS90:5742-5746.
Lee, P.W.K. et al. (1981)Virology, 108:134-146.
Levitzki, A. (1994)Eur. J. Biochem. 226:1-13.
Lowe, S. W. et al. (1994)Science, 266:807-810.
Mah et al., “The N-terminal quarter of reovirus cell attachment protein sigma 1 possesses intrinsic virion-anchoring function”Virology179(1):95-103 (1990).
Migliaccio et al. (1996),EMBO J15:1292-1300.
Migliaccio et al. (1998),EMBO J17:2008-2018.
Millis, NE et al. (1995)Cancer Res. 55:1444-1447.
Nagy et al. (1989)Biochim Biophys Acta948:305-326.
Paul R. W. et al. (1989)Virology172:382-385.
Pietras et al. (1994),Oncogene9:1829-1838.
Raybaud-Diogene. H. et al. (1997)J. Clin. Oncology, 15(3):1030-1038.
Rosen, L. (1960)Am. J. Hyg.71:242-249.
Shackney et al. (1998),Clin Cancer Res4:913-928.
Slamon et al. (1989),Science244:707-712.
Smith, R.E. et al., (1969)Virology, 39:791-800.
Spandiodos (1987),Anticancer Res7:991-996.
Stanley, N.F. (1967)Br. Med. Bull. 23:150-154.
Strong, J.E. et al.,(1993)Virology, 197:405-411.
Strong, J.E. and Lee, P.W.K., (1996)J. Virol., 70:612-616.
Strong, J.E. et al.,(1998)EMBO J, 17:3351-3362.
Turner and Duncan, “Site directed mutagenesis of the C-terminal portion of reovirus protein signa1:evidence for a conformation-dependent receptor binding domain”Virology186(1):219-227 (1992).
Verbeek et al. (1996)J Path180:383-388.
Wiessmuller, L. and Wittinghofer, F. (1994),Cellular Signaling6(3):247-267.
Zhou et al. (1989),Oncogene4:105-108.
Ikeda, K., et al., “Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses”,Nature Medicine5:881-887.
Ikeda, K., et al., “Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant”,J. Virology74:4765-4775.
Tyler, K.L., et al., “Molecular basis of viral apoptosis: Reovirus-induced apoptosis is associated with activation of nuclear transcription factor NfkappaB via the MAP kinases MEKK1 and NIK”,Neurology52:A186 (abstract).
Thirukkumaran, C.M., et al., “Reovirus induces apoptosis in breast and prostate cell lines and activates Nf-kappaβin the nucleus: Implications for a prognostic factor in successful reovirus therapy”,Proceedings of the American Association for Cancer Research Annual42:455 (abstract).

Affiliated with

Also associated with

Rating

Methods for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3605135